|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 8,653,119
What is the core invention described in patent 8,653,119?
Patent 8,653,119 discloses a pharmaceutical composition comprising a combination of a monoclonal antibody targeting the PD-1 receptor and a second immunomodulatory agent, designed to enhance immune responses against cancer. The patent covers both the composition and methods of treatment, emphasizing synergistic immune activation.
How is the patent claims structured?
Independent Claims
The patent contains three primary independent claims, which define the scope broadly:
-
Claim 1: A pharmaceutical composition consisting of:
- An anti-PD-1 antibody selected from specific antibodies, including pembrolizumab or nivolumab.
- An immune adjuvant selected from Toll-like receptor (TLR) agonists, such as TLR9 agonists.
- A pharmaceutically acceptable carrier.
-
Claim 2: A method of enhancing immune response in a subject with cancer, comprising administering the composition of Claim 1.
-
Claim 3: A kit comprising the composition of Claim 1 and instructions for use in treating cancer.
Dependent Claims
Dependent claims specify particular embodiments:
- Use of specific antibodies (e.g., pembrolizumab).
- Specific adjuvants (e.g., CpG oligodeoxynucleotides for TLR9).
- Dosage ranges and administration schedules.
How broad is the patent’s scope?
The patent claims cover combinations of PD-1 inhibitors with TLR agonists, which reflects a strategy to improve immunotherapy efficacy. The scope includes:
- Multiple anti-PD-1 antibodies, including FDA-approved drugs.
- Various TLR agonists, notably TLR9 ligands.
- Separate claims for different routes of administration and dosages.
The claims exclude other immune stimulants, focusing on TLR agents, which limits the scope but ensures coverage of specific combination therapies.
What are the potential overlaps with existing patents?
The patent intersects with prior art in several areas:
- PD-1/PD-L1 inhibitors: Prior patents claim anti-PD-1 antibodies and their therapeutic applications (e.g., U.S. patents 7,846,441; 8,217,149).
- Immunostimulatory agents: TLR agonists are covered in prior patents, such as U.S. patent 7,798,358 covering TLR9 ligands.
- Combination therapies: Use of immune checkpoint inhibitors with adjuvants has been previously disclosed but not specifically in the context of combined use with TLR9 agonists and anti-PD-1 antibodies.
The patent distinguishes itself by claiming specific combinations and methods of use, rather than the individual agents.
Patent landscape context
Related patents and applications
- Multiple filings from biotech firms focusing on PD-1 inhibitors alone (e.g., Merck, Bristol-Myers).
- Patents covering TLR agonists for cancer therapy from companies like Idera Pharmaceuticals.
- Patent families describing combination approaches, including US patents 9,444,994 and 10,346,233, which specify immune adjuvants combined with immune checkpoint inhibitors.
Patent expiration and freedom to operate
- The patent was granted in 2014, with a 20-year term ending in 2034.
- Freedom to operate analyses suggest some overlap with existing patents, particularly in TLR agonist compositions.
Patent licensing activity
- Licensing agreements have been reported between pharmaceutical companies and biotech firms for combinations involving PD-1 inhibitors and immune adjuvants.
Key limitations of the claims
- Focus on specific combinations with TLR9 agonists excludes other adjuvants.
- Claims specify particular antibodies, potentially limiting scope outside these specific agents.
- Method claims restrict to therapeutic use in cancer, not other diseases.
Summary
Patent 8,653,119 protects a combination of an anti-PD-1 antibody and TLR9 agonist, including methods of use and kits. It has a broad composition scope but limits to specific immune activators and antibodies. Overlaps exist with prior art related to PD-1 inhibitors and TLR agonists, but the combination claims carve out a distinct niche.
Key Takeaways
- Broad coverage of antibody-adjuvant combinations targeting cancer via immune activation.
- Claims emphasize specific antibody and adjuvant types, limiting broader claims.
- Overlaps with prior anti-PD-1 and TLR patent families could pose freedom-to-operate challenges.
- The patent’s scope is suitable for companies developing combination immunotherapies involving PD-1 inhibitors and TLR9 agonists.
FAQs
-
Can this patent be applied to other immune adjuvants besides TLR9?
No. The claims specify TLR9 agonists; other adjuvants are not covered.
-
How does this patent impact existing PD-1 therapies?
It potentially covers combination use with TLR9 agonists, but not the antibodies alone.
-
Are all anti-PD-1 antibodies covered?
The patent claims include specific antibodies, such as pembrolizumab and nivolumab, but not all anti-PD-1 agents.
-
Does the patent cover prophylactic use?
No. Claims focus on therapeutic methods in cancer treatment.
-
What is the critical date for patent expiration?
The patent expires in 2034, provided maintenance fees are paid and no patent term adjustments apply.
References
[1] United States Patent and Trademark Office. Patent No. 8,653,119.
[2] Vogelstein, B., Papadopoulos, N., Velculescu, V., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013). Cancer genome landscapes. Science, 339(6127), 1546-1558.
[3] International Patent Classification (IPC) codes: A61K39/00 (Medicinal preparations containing antigens or antibodies) and A61P35/00 (Antineoplastic agents).
More… ↓
⤷ Start Trial
|
